Artivion (NYSE:AORT) Shares Gap Down – Should You Sell?

Artivion, Inc. (NYSE:AORT)’s share price gapped down prior to trading on Thursday . The stock had previously closed at $36.62, but opened at $33.60. Artivion shares last traded at $33.1650, with a volume of 15,025 shares traded.

Analyst Upgrades and Downgrades

AORT has been the topic of a number of research analyst reports. Stifel Nicolaus set a $55.00 target price on Artivion in a research report on Thursday, March 5th. Wall Street Zen downgraded Artivion from a “buy” rating to a “hold” rating in a research report on Saturday, February 14th. Needham & Company LLC restated a “buy” rating and issued a $58.00 price objective on shares of Artivion in a report on Monday, February 2nd. Canaccord Genuity Group decreased their target price on shares of Artivion from $51.00 to $48.00 and set a “buy” rating on the stock in a research report on Friday, February 13th. Finally, Weiss Ratings raised shares of Artivion from a “sell (d)” rating to a “hold (c-)” rating in a research note on Friday, February 20th. Six analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to MarketBeat.com, Artivion presently has a consensus rating of “Moderate Buy” and a consensus price target of $50.47.

Artivion Stock Up 0.1%

The business has a 50 day simple moving average of $38.08 and a 200 day simple moving average of $41.95. The company has a market capitalization of $1.64 billion, a price-to-earnings ratio of 170.83 and a beta of 1.63. The company has a debt-to-equity ratio of 0.49, a current ratio of 3.53 and a quick ratio of 2.62.

Artivion (NYSE:AORT) last posted its quarterly earnings data on Thursday, February 12th. The company reported $0.17 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.14 by $0.03. Artivion had a return on equity of 7.43% and a net margin of 2.21%.The firm had revenue of $118.30 million for the quarter, compared to the consensus estimate of $116.42 million. The business’s quarterly revenue was up 19.2% compared to the same quarter last year. As a group, equities analysts predict that Artivion, Inc. will post 0.37 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Artivion news, SVP Jean F. Holloway sold 8,962 shares of the business’s stock in a transaction that occurred on Wednesday, March 4th. The shares were sold at an average price of $38.00, for a total transaction of $340,556.00. Following the completion of the transaction, the senior vice president owned 185,095 shares in the company, valued at $7,033,610. The trade was a 4.62% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO James P. Mackin sold 20,962 shares of the stock in a transaction that occurred on Monday, February 23rd. The shares were sold at an average price of $37.59, for a total transaction of $787,961.58. Following the completion of the sale, the chief executive officer directly owned 780,031 shares in the company, valued at approximately $29,321,365.29. This represents a 2.62% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last ninety days, insiders sold 133,043 shares of company stock valued at $4,977,158. Corporate insiders own 7.60% of the company’s stock.

Institutional Investors Weigh In On Artivion

Institutional investors have recently modified their holdings of the company. Caitong International Asset Management Co. Ltd acquired a new position in shares of Artivion during the 3rd quarter worth about $27,000. Aster Capital Management DIFC Ltd raised its position in shares of Artivion by 402.3% during the 3rd quarter. Aster Capital Management DIFC Ltd now owns 648 shares of the company’s stock worth $27,000 after acquiring an additional 519 shares in the last quarter. Rockefeller Capital Management L.P. lifted its stake in Artivion by 150.0% during the fourth quarter. Rockefeller Capital Management L.P. now owns 665 shares of the company’s stock worth $30,000 after purchasing an additional 399 shares during the last quarter. Larson Financial Group LLC boosted its holdings in Artivion by 148.5% in the fourth quarter. Larson Financial Group LLC now owns 942 shares of the company’s stock valued at $43,000 after purchasing an additional 563 shares in the last quarter. Finally, USA Financial Formulas boosted its holdings in Artivion by 163.5% in the fourth quarter. USA Financial Formulas now owns 1,133 shares of the company’s stock valued at $52,000 after purchasing an additional 703 shares in the last quarter. 86.37% of the stock is owned by hedge funds and other institutional investors.

Artivion Company Profile

Artivion, Inc (NYSE: AORT) is a global medical technology company that develops, manufactures and markets implantable tissue products and surgical devices for cardiac and vascular surgery. The company’s portfolio includes biologic implants derived from human and animal tissue, such as allografts and xenografts, as well as synthetic scaffolds and surgical adhesives. These products are designed to repair, reinforce or replace damaged cardiovascular and thoracic tissues during procedures such as aortic repair, heart valve surgery and vascular reconstruction.

Originally founded in 1984 under the name CryoLife, the company rebranded as Artivion in early 2022 to reflect its broader mission in cardiovascular innovation.